A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration
Latest Information Update: 01 Sep 2022
At a glance
- Drugs CBP-174 (Primary)
- Indications Pruritus
- Focus Adverse reactions; First in man
- Sponsors Connect Biopharma Australia
- 30 Aug 2022 According to a Connect Biopharma Holdings Limited media release, a total of 72 subjects were dosed with 8 subjects included in each cohort, whereby 54 and 18 subjects received CBP-174 and placebo, respectively.
- 30 Aug 2022 Results presented in a Connect Biopharma Holdings Limited Media Release.
- 14 Jun 2022 Status changed from recruiting to completed.